Trulieve Cannabis (TCNNF) EBITDA Margin (2020 - 2026)

Trulieve Cannabis' EBITDA Margin history runs 7 years deep, the most recent figure standing at 12.46% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 127.0% year-over-year to 12.46%; the TTM figure through Mar 2026 stood at 12.47% (up 530.0% YoY), while the FY2025 annual figure was 14.28%, up 171.0% from the prior year.
• EBITDA Margin was 12.46% for Q1 2026 at Trulieve Cannabis, up from 5.22% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 19.62% in Q2 2022 to a low of 103.37% in Q2 2023.
• Historically, EBITDA Margin has averaged 3.42% across 5 years, with a median of 12.46% in 2026.
• The sharpest annual moves came in 2023 and 2024: EBITDA Margin plunged 12299 bps in 2023, then jumped 11977 bps in 2024.
• A 5-year view of EBITDA Margin shows it stood at 0.67% in 2022, then jumped by 1514 bps to 9.51% in 2023, then tumbled by 95 bps to 0.43% in 2024, then surged by 1101 bps to 5.22% in 2025, then surged by 139 bps to 12.46% in 2026.
• The last three EBITDA Margin figures came in at 12.46% (Q1 2026), 5.22% (Q4 2025), and 14.66% (Q3 2025), per Business Quant data.